Retatrutide Dosage Chart: Complete Titration Guide & What Phase 3 Trials Tell Us

In late 2025, Eli Lilly made headlines with Phase 3 data showing their investigational weight-loss drug retatrutide produced average weight loss of 28.7% — numbers that surpass every medication currently on the market. If you’ve been following the GLP-1 space and wondering whether retatrutide could be your next step, or just trying to understand how the dosing works, this guide covers everything.

We’ll walk through what makes retatrutide different from Ozempic and Zepbound, the complete retatrutide dosage chart from trials, what the clinical data actually shows, and the realistic timeline to FDA approval.

What Is Retatrutide?

Retatrutide (also known by its development code LY3437943) is an investigational once-weekly injectable medication developed by Eli Lilly. It is the world’s first triple hormone receptor agonist — meaning a single molecule that activates three separate hormone receptors in your body simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon.

To understand why this matters, think of it this way. Ozempic (semaglutide) activates one receptor (GLP-1) and produces about 15% average weight loss. Zepbound (tirzepatide) activates two receptors (GLP-1 + GIP) and produces 20–22% average weight loss. Retatrutide activates all three — GLP-1, GIP, and glucagon — and early Phase 3 data shows 28.7% average weight loss. Each additional receptor seems to add meaningful weight loss on top.

How Each Receptor Contributes

GLP-1 receptor: Slows stomach emptying, reduces appetite, stimulates insulin release when blood sugar is high, and affects brain circuits involved in hunger. This is the primary target of Ozempic and Wegovy.

GIP receptor: Enhances insulin secretion and may affect how your body processes and stores fat. Tirzepatide (Zepbound/Mounjaro) added this to GLP-1 activation.

Glucagon receptor: This is retatrutide’s unique addition. Glucagon increases energy expenditure — essentially causing your body to burn more calories at rest. It also helps break down fat in the liver. No currently approved weight-loss medication activates glucagon.

How Retatrutide Compares to Other Medications

Retatrutide Dosage Chart: The Complete Titration Schedule

Because retatrutide is still investigational, there is no FDA-approved dosage label yet. The titration schedules below come directly from the TRIUMPH Phase 3 clinical trial program. All participants start at 2 mg once weekly and escalate every four weeks in a step-wise fashion. The target dose depends on which part of the trial program a participant is enrolled in.

Note: The TRIUMPH program is also exploring a 4 mg maintenance dose for a separate arm of the trials. This lower maintenance dose may be appropriate for people who achieve their goals at 4–6 mg or who need to reduce side effects. Results from this arm are expected in 2026.

Clinical Trial Results: Phase 2 and Phase 3 Data

Retatrutide has now produced data across multiple phases of clinical trials involving thousands of participants. Here’s what the research shows.

Phase 2 Results: Setting the Stage

The original Phase 2 trial enrolled 338 adults without diabetes who were overweight or obese (BMI ≥27) and ran for 48 weeks. Participants were divided into six groups receiving different doses. The key finding: the more medication participants took, the more weight they lost, with a clear dose-response relationship.

At the two highest doses (8 mg and 12 mg groups), every single participant lost at least 5% of their starting weight — a threshold considered clinically meaningful. Participants also saw improvements in waist circumference, blood pressure, and blood sugar levels.

Phase 3 TRIUMPH-4 Results: December 2025

Eli Lilly published TRIUMPH-4 results in December 2025, representing the most mature Phase 3 data available. This trial enrolled 445 participants aged 18 and older with a BMI of ≥27 who also had knee osteoarthritis (a weight-related condition).

At 68 weeks, the results were striking:

• Retatrutide 12 mg: 28.7% average body weight loss. 58.6% of participants achieved ≥25% weight loss; 39.4% achieved ≥30% weight loss.
• Retatrutide 9 mg: 26.4% average body weight loss. Comparable improvements in knee pain and function scores.
• Placebo: 2.1% weight loss. Serves as the comparison baseline.

Perhaps the most important finding: the weight-loss curve had not plateaued at 68 weeks. Participants were still losing weight at the final data point, suggesting that even greater total weight loss would be achievable with longer treatment. The longer TRIUMPH-1 trial (targeting 80 weeks) is expected to show results exceeding 30%.

To put those numbers in concrete terms: for someone starting at 250 pounds, 28.7% weight loss equals 71.8 pounds. For a 200-pound person, it’s about 57 pounds. These are results previously achievable only with bariatric surgery.

Side Effects and Safety

Retatrutide’s side effect profile is broadly similar to other GLP-1 medications, with gastrointestinal issues being the most common concern. However, the three-receptor mechanism does introduce some differences worth knowing about.

Common Side Effects

• Nausea (most common, especially during dose escalation)
• Diarrhea
• Constipation
• Vomiting
• Decreased appetite (part of how it works)
• Dysesthesia (unusual skin sensations — less common but more specific to retatrutide than other GLP-1 drugs)

Most GI side effects were mild to moderate and improved over time. The slow titration schedule was specifically designed to minimize these effects — clinical data showed that rushing the dose escalation nearly doubled GI side-effect rates, which is why each dose step must be maintained for at least four weeks.

Discontinuation Rates

In the TRIUMPH-4 trial, discontinuation due to adverse events was higher than many previously approved GLP-1 medications: 12.2% at 9 mg and 18.2% at 12 mg (compared to 4.0% with placebo). This is notably higher than discontinuation rates seen with Ozempic or Wegovy (typically 5–10%), which likely reflects the stronger pharmacological activity of activating three receptors rather than one or two.

These rates need to be weighed against the dramatically higher weight loss. Whether the higher discontinuation risk is acceptable depends on your individual health situation — something to discuss carefully with a healthcare provider.

Additional Safety Notes

Like all GLP-1 receptor agonists, retatrutide will likely carry a boxed warning about thyroid C-cell tumors if approved (based on animal studies), and is expected to be contraindicated in people with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Full safety data, including long-term effects, will be assessed before any FDA submission.

Notably, the glucagon receptor activation in retatrutide may affect blood glucose differently than other GLP-1 drugs. Glucagon naturally raises blood sugar — the drug is designed so this effect is balanced by the GLP-1 and GIP activity, but how it performs in people with type 2 diabetes or hypoglycemia risk is an area under active study in the TRIUMPH program.

How to Access Retatrutide in 2026

The single most important thing to understand: retatrutide is not FDA-approved and is not commercially available. As of early 2026, the only way to access retatrutide is through participation in an active Eli Lilly clinical trial.

The TRIUMPH Clinical Trial Program

The TRIUMPH program has enrolled more than 5,800 participants across multiple trials, each targeting different patient populations and endpoints:

• TRIUMPH-1 & TRIUMPH-2: Adults with obesity or overweight. Testing 4 mg, 9 mg, and 12 mg doses. 80-week duration — the longest and most comprehensive trial.
• TRIUMPH-3 & TRIUMPH-4: Adults with obesity plus specific comorbidities (type 2 diabetes, obstructive sleep apnea, knee osteoarthritis). Testing 9 mg and 12 mg doses.

To find open trials and check eligibility, search ClinicalTrials.gov for “retatrutide” or “LY3437943.” Enrollment for some arms may be closed as the trials near completion; additional trials studying retatrutide in other conditions are being planned.

Warning About Unregulated Sources

Online searches will turn up websites selling “retatrutide” or “LY3437943” from compounding pharmacies or research chemical suppliers. Do not purchase retatrutide from these sources. Products sold outside of clinical trials and licensed pharmaceutical channels have not been tested for purity, potency, or safety. You have no way of knowing what you’re actually getting, and dosing an unapproved investigational drug without medical supervision carries serious risks.

When Will Retatrutide Be Available? The Approval Timeline

Based on the current state of the TRIUMPH trials and Eli Lilly’s likely regulatory strategy, here’s a realistic timeline:

• 2026: Final TRIUMPH trial results, including the pivotal TRIUMPH-1 and TRIUMPH-2 long-term data. Eli Lilly will compile the complete efficacy and safety dataset for FDA submission.
• Late 2026 to early 2027: Expected FDA submission of New Drug Application (NDA). FDA review typically takes 6–12 months for priority review.
• 2027: Potential FDA approval and initial commercial launch. Industry analysts forecast 2027 as the most likely approval year.
• 2031 forecast: Market analysts at GlobalData project retatrutide sales reaching $15.6 billion — a figure that reflects expected demand if it performs in the real world as it has in trials.

These timelines can shift based on regulatory discussions, trial completion dates, and FDA priority review decisions. Keep an eye on Eli Lilly’s investor communications and FDA announcements for updates.

Frequently Asked Questions

The Bottom Line

Retatrutide represents a genuine step forward in weight-loss medicine — not just incremental improvement, but a meaningful leap. By activating three hormone receptors (GLP-1, GIP, and glucagon) instead of the two targeted by the current best-in-class medication (tirzepatide), it produces weight loss of 26–29% at Phase 3 doses. To put that in context: a 250-pound person taking the 12 mg dose could expect to lose, on average, over 70 pounds.

The retatrutide dosage follows a careful five-step titration schedule starting at 2 mg weekly and escalating every four weeks to a maximum of 12 mg. Rushing this schedule was shown to nearly double GI side effects in trials, so patience with the titration is medically important, not just a recommendation.

The practical reality for 2026: retatrutide is not approved, and the only legitimate way to access it is through a clinical trial. FDA approval is anticipated around 2027, with commercial availability to follow. If you’re managing obesity now, Zepbound (tirzepatide) and Wegovy (semaglutide) remain the best available options — both are far more effective than lifestyle modification alone, and you won’t need to wait two years. Talk to your healthcare provider about which option makes the most sense for your situation today.